Dr. Badros is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
22 S. Greene St
Baltimore, MD 21201Phone+1 410-328-1230Fax+1 410-328-1975- Is this information wrong?
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1994 - 1996
MedStar Health/Harbor HospitalResidency, Internal Medicine, 1990 - 1993
Ain Shams University Faculty of MedicineClass of 1985
Certifications & Licensure
MD State Medical License 1991 - 2024
AR State Medical License 1998 - 2002
DC State Medical License 1994 - 1998
NY State Medical License 1993 - 1994- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2002 Sep 01
- FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 01
- Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Bad...> ;British Journal of Haematology. 2024 Mar 19
- Addressing the disparities: the approach to the African American patient with multiple myeloma.Bhutani, M., Blue, B., Cole, C., Badros, A., Usmani, S., Nooka, A., Bernal-Mizrachi, L., Mikhael, J.> ;Blood Cancer Journal. 2023 Dec 18
- Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.Yamini K Kathari, Haroon Ahmad, Michael E Kallen, Rima Koka, Destiny Omili, Thierry Iraguha, Jean Clement, Lily Pham, Mazhar Khalid, Xiaoxuan Fan, Etse Gebru, Patricia...> ;Haematologica. 2024 Feb 1
- Join now to see all
Abstracts/Posters
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)Ashraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Ashraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierAshraf Z. Badros, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis (BKV-HC) Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Novel Approaches to Newly Diagnosed Plasma Cell Dyscrasias2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
International Myeloma Foundation Launches Baltimore-Area Campaign to Raise Disease Awareness and Improve Outcomes in the African-American CommunitySeptember 9th, 2021
Pembrolizumab Combo Active in Relapsed/Refractory MyelomaMay 16th, 2017
Hospital Affiliations
University of Maryland Medical CenterBaltimore, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
